TMPRSS2 contains a trypsin-like extracellular catalytic domain, and therefore, the salt bridging feature may help screen and repurpose existing drugs against TMPRSS2 for COVID-19 treatment. This evidence concerns the gene TMPRSS2 and COVID-19.